UA115455C2 - Спосіб одержання сполук для застосування при лікуванні раку - Google Patents

Спосіб одержання сполук для застосування при лікуванні раку

Info

Publication number
UA115455C2
UA115455C2 UAA201504532A UAA201504532A UA115455C2 UA 115455 C2 UA115455 C2 UA 115455C2 UA A201504532 A UAA201504532 A UA A201504532A UA A201504532 A UAA201504532 A UA A201504532A UA 115455 C2 UA115455 C2 UA 115455C2
Authority
UA
Ukraine
Prior art keywords
cancer treatment
preparing compounds
compound
formula
mek
Prior art date
Application number
UAA201504532A
Other languages
English (en)
Ukrainian (uk)
Inventor
Срірам Наганатхан
Натхан Гуз
Меттью Пфайффер
К. Грегорі Сауелл
Трейсі Бостік
Джейсон Ян
Аміт Срівастава
Original Assignee
Екселіксіс, Інк.
Дженентек, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Екселіксіс, Інк., Дженентек, Інк. filed Critical Екселіксіс, Інк.
Publication of UA115455C2 publication Critical patent/UA115455C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
UAA201504532A 2012-10-12 2013-10-14 Спосіб одержання сполук для застосування при лікуванні раку UA115455C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
UA115455C2 true UA115455C2 (uk) 2017-11-10

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201504532A UA115455C2 (uk) 2012-10-12 2013-10-14 Спосіб одержання сполук для застосування при лікуванні раку

Country Status (31)

Country Link
US (4) US9771347B2 (enExample)
EP (1) EP2909188B1 (enExample)
JP (2) JP6300042B2 (enExample)
KR (1) KR102204520B1 (enExample)
CN (2) CN104837826B (enExample)
AU (1) AU2013328929B2 (enExample)
BR (1) BR112015008113B1 (enExample)
CA (1) CA2889466C (enExample)
CL (1) CL2015000926A1 (enExample)
CR (2) CR20200237A (enExample)
EA (1) EA030613B1 (enExample)
ES (1) ES2671502T3 (enExample)
GE (1) GEP201706690B (enExample)
HK (1) HK1213567A1 (enExample)
HR (1) HRP20180670T1 (enExample)
IL (1) IL238116B (enExample)
IN (1) IN2015DN03928A (enExample)
MA (1) MA38085B1 (enExample)
MX (2) MX372708B (enExample)
MY (1) MY186549A (enExample)
NZ (1) NZ706723A (enExample)
PE (3) PE20151494A1 (enExample)
PH (1) PH12015500785B1 (enExample)
PL (1) PL2909188T3 (enExample)
SA (1) SA515360271B1 (enExample)
SG (1) SG11201502795VA (enExample)
SI (1) SI2909188T1 (enExample)
TR (1) TR201807861T4 (enExample)
UA (1) UA115455C2 (enExample)
WO (1) WO2014059422A1 (enExample)
ZA (1) ZA201502349B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115455C2 (uk) 2012-10-12 2017-11-10 Екселіксіс, Інк. Спосіб одержання сполук для застосування при лікуванні раку
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN108135854B (zh) 2015-06-30 2022-03-11 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
MX2019001635A (es) 2016-08-12 2019-06-10 Genentech Inc Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
BR112019005815A2 (pt) 2016-09-29 2019-06-25 Genentech Inc métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
US20240173329A1 (en) 2021-03-09 2024-05-30 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
US20240366609A1 (en) 2021-04-06 2024-11-07 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
WO1995026956A1 (en) 1994-04-01 1995-10-12 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
AU757046B2 (en) 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
AU756586C (en) * 1997-07-01 2004-01-29 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
EP1140046A1 (en) 1998-12-15 2001-10-10 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
EP1140291B1 (en) 1998-12-22 2005-11-23 Warner-Lambert Company Llc Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
WO2000040235A2 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
HUP0105113A3 (en) 1999-01-13 2004-11-29 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
ATE309205T1 (de) 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
IL144215A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
HUP0202381A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
NZ515567A (en) 1999-07-16 2004-03-26 Warner Lambert Co Method for treating chronic pain using MEK inhibitors
AU6068600A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
ES2208364T3 (es) 1999-07-16 2004-06-16 Warner-Lambert Company Llc Procedimiento para tratar dolor cronico usando inhibidores de mek.
EP1216228B1 (en) 1999-09-17 2008-10-29 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
HUP0300828A2 (hu) * 2000-08-25 2003-09-29 Warner-Lambert Company Llc Eljárás N-aril-antranilsavak és e vegyületek származékainak elżállítására
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
CA2460118A1 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー N−(4−置換フェニル)−アントラニル酸ヒドロキサメートエステル
AR038972A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
PL401638A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1515727A4 (en) 2002-06-11 2009-04-08 Merck & Co Inc (HALO-BENZO CARBONYL) HETEROBICYCLIC P38 KINASE INHIBITION
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US20060094674A1 (en) 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
EP1606283B1 (en) 2003-03-03 2008-10-08 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05013227A (es) 2003-06-20 2006-03-09 Celltech R&D Ltd Derivados de tienopiridona como inhibidores de cinasa.
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
EP1674452A4 (en) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
JP4768628B2 (ja) 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Mekの二環系阻害剤及びその使用方法
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004299198A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivates
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
PT1802579E (pt) * 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
JP5311673B2 (ja) * 2006-12-14 2013-10-09 エグゼリクシス, インコーポレイテッド Mek阻害剤の使用方法
UA115455C2 (uk) 2012-10-12 2017-11-10 Екселіксіс, Інк. Спосіб одержання сполук для застосування при лікуванні раку
BR112016017648B1 (pt) 2014-02-07 2021-01-19 Sumitomo Chemical Company, Limited método para produção de (r)-1,1,3-trimetil-4-aminoindano
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
HRP20180670T1 (hr) 2018-07-13
US20150210668A1 (en) 2015-07-30
HK1213567A1 (zh) 2016-07-08
US10793541B2 (en) 2020-10-06
KR20150067339A (ko) 2015-06-17
CA2889466C (en) 2021-09-14
BR112015008113A2 (pt) 2017-07-04
AU2013328929B2 (en) 2018-01-04
GEP201706690B (en) 2017-06-26
US9771347B2 (en) 2017-09-26
TR201807861T4 (tr) 2018-06-21
CN108948043B (zh) 2021-05-04
PE20151494A1 (es) 2015-11-06
MX2020005533A (es) 2020-10-12
PE20191818A1 (es) 2019-12-27
MA38085A1 (fr) 2018-08-31
AU2013328929A1 (en) 2015-04-30
EP2909188B1 (en) 2018-03-07
ZA201502349B (en) 2019-12-18
CN108948043A (zh) 2018-12-07
PH12015500785A1 (en) 2015-06-15
CR20150245A (es) 2015-11-19
PE20200387A1 (es) 2020-02-24
EA201590700A1 (ru) 2015-09-30
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
US10239858B2 (en) 2019-03-26
NZ706723A (en) 2018-07-27
US20170349569A1 (en) 2017-12-07
CN104837826A (zh) 2015-08-12
PH12015500785B1 (en) 2015-06-15
MX2015004660A (es) 2015-08-07
SG11201502795VA (en) 2015-05-28
JP6300042B2 (ja) 2018-03-28
BR112015008113B1 (pt) 2022-05-24
SI2909188T1 (en) 2018-07-31
KR102204520B1 (ko) 2021-01-20
CN104837826B (zh) 2018-07-27
MX372708B (es) 2020-05-29
MY186549A (en) 2021-07-26
WO2014059422A1 (en) 2014-04-17
US20200392104A1 (en) 2020-12-17
HK1213878A1 (en) 2016-07-15
EP2909188A1 (en) 2015-08-26
JP2015533175A (ja) 2015-11-19
US11414396B2 (en) 2022-08-16
CR20200237A (es) 2020-07-26
ES2671502T3 (es) 2018-06-06
IL238116B (en) 2018-06-28
CL2015000926A1 (es) 2015-08-28
CA2889466A1 (en) 2014-04-17
IN2015DN03928A (enExample) 2015-10-02
SA515360271B1 (ar) 2016-05-19
EA030613B1 (ru) 2018-08-31
PL2909188T3 (pl) 2018-08-31
JP2018052973A (ja) 2018-04-05

Similar Documents

Publication Publication Date Title
UA115455C2 (uk) Спосіб одержання сполук для застосування при лікуванні раку
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
MX380092B (es) Tratamiento de la osteoartritis.
PH12016500225B1 (en) Novel quinoline-substituted compound
TN2014000093A1 (en) Method of treating gastrointestinal stromal tumors
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
PH12016500963A1 (en) Novel dgat2 inhibitors
SG10201900564WA (en) Methods for treating cancer
UA114937C2 (uk) Спосіб стимулювання росту рослин із застосуванням карбоксамідних похідних
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
MX357763B (es) Tratamiento para cancer pancreatico.
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
EA201270237A1 (ru) Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения, содержащие магний
EA201590656A1 (ru) Азаиндолины
EA201490725A1 (ru) Способ лечения мукоэпидермоидной карциномы
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
PL418655A1 (pl) Kwas 3,7,11,15-tetrametylo-3-winyloheksadekanowy oraz sposób otrzymywania kwasu 3,7,11,15-tetrametylo-3-winyloheksadekanowego